Alector (ALEC) Current Deferred Revenue (2018 - 2026)
Alector's (ALEC) quarterly Current Deferred Revenue came in at $6.7 million in Q1 2026, down 69.23% year-over-year from $21.8 million in Q1 2025, and up 0.58% quarter-over-quarter from $6.7 million in Q4 2025.
Analysis
Alector (ALEC) Current Deferred Revenue (2018 - 2026) Analysis & Trends
Alector (ALEC) has reported Current Deferred Revenue for 9 consecutive years, with $6.7 million the latest figure, recorded in Q1 2026.
- On a quarterly basis, Current Deferred Revenue fell 69.23% year-over-year to $6.7 million in Q1 2026; TTM through Mar 2026 was $6.7 million, a 69.23% decrease from a year earlier, with the FY2025 full-year figure at $6.7 million, down 71.75% from the prior year.
- Current Deferred Revenue was $6.7 million for Q1 2026 at Alector, up from $6.7 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $465.4 million in Q2 2022 and troughed at $6.7 million in Q4 2025.
- A 5-year average of $130.6 million and a median of $64.0 million in 2024 frame the typical range for Current Deferred Revenue.
- The widest YoY moves for Current Deferred Revenue: up 282.73% in 2022, down 84.34% in 2022.
- Over 5 years, Current Deferred Revenue stood at $48.2 million in 2022, then surged by 72.04% to $83.0 million in 2023, then plunged by 71.48% to $23.7 million in 2024, then plunged by 71.75% to $6.7 million in 2025, then grew by 0.58% to $6.7 million in 2026.
- The last three Current Deferred Revenue figures came in at $6.7 million (Q1 2026), $6.7 million (Q4 2025), and $11.7 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Alector | 274.68 Mn | 101.88 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 6.72 Mn |
| Dec 31, 2025 | 6.68 Mn |
| Sep 30, 2025 | 11.74 Mn |
| Jun 30, 2025 | 13.40 Mn |
| Mar 31, 2025 | 21.85 Mn |
| Dec 31, 2024 | 23.66 Mn |
| Sep 30, 2024 | 55.43 Mn |
| Jun 30, 2024 | 63.96 Mn |
| Mar 31, 2024 | 73.35 Mn |
| Dec 31, 2023 | 82.98 Mn |
| Sep 30, 2023 | 80.56 Mn |
| Jun 30, 2023 | 267.20 Mn |
| Mar 31, 2023 | 433.60 Mn |
| Dec 31, 2022 | 48.23 Mn |
| Sep 30, 2022 | 119.68 Mn |
| Jun 30, 2022 | 465.40 Mn |
| Mar 31, 2022 | 444.90 Mn |
| Dec 31, 2021 | 307.90 Mn |
| Sep 30, 2021 | 320.20 Mn |
| Jun 30, 2021 | 121.60 Mn |